ProTEct-MS Extension Trial Launches to Test Higher Temelimab Doses

ProTEct-MS Extension Trial Launches to Test Higher Temelimab Doses

307304

ProTEct-MS Extension Trial Launches to Test Higher Temelimab Doses

The first patient who completed the ProTEct-MS Phase 2 clinical trial assessing temelimab as a treatment for relapsing forms of multiple sclerosis (MS) has entered the trial’s extension part. In the open-label extension trial, patients will switch to or continue to receive temelimab at least until next spring, when the core trial findings are expected. “We are grateful to the patients who have agreed to participate in this important study and are delighted to offer them…

You must be logged in to read/download the full post.